Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Immunological biomarkers as indicators for outcome after discontinuation of nucleos(t)ide analogue therapy in patients with HBeAg-negative chronic hepatitis B.

Kranidioti H, Manolakopoulos S, Kontos G, Breen MS, Kourikou A, Deutsch M, Quesada-Del-Bosque ME, Martinez-Nunez RT, Naiyer MM, Woelk CH, Sanchez-Elsner T, Hadziyannis E, Papatheodoridis G, Khakoo SI.

J Viral Hepat. 2019 Jun;26(6):697-709. doi: 10.1111/jvh.13068. Epub 2019 Feb 27.

PMID:
30702196
2.

Interleukin-17A and B-cell activating factor in chronic hepatitis C patients with or without asymptomatic mixed cryoglobulinemia: effects of antiviral treatment and correlations with vitamin D.

Konstantinides P, Alexopoulou A, Hadziyannis E, Kanellopoulou T, Dourakis SP.

Ann Gastroenterol. 2018 Nov-Dec;31(6):705-711. doi: 10.20524/aog.2018.0310. Epub 2018 Sep 14.

3.

Viral Biomarkers in Chronic HBeAg Negative HBV Infection.

Hadziyannis E, Laras A.

Genes (Basel). 2018 Sep 27;9(10). pii: E469. doi: 10.3390/genes9100469. Review.

4.

Human beta-defensin-1 is a highly predictive marker of mortality in patients with acute-on-chronic liver failure.

Mani I, Alexopoulou A, Vasilieva L, Hadziyannis E, Agiasotelli D, Bei M, Alexopoulos T, Dourakis SP.

Liver Int. 2019 Feb;39(2):299-306. doi: 10.1111/liv.13977. Epub 2018 Oct 24.

PMID:
30261128
5.

Correction: DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B.

Papatheodoridis GV, Rigopoulou EI, Papatheodoridi M, Zachou K, Xourafas V, Gatselis N, Hadziyannis E, Vlachogiannakos J, Manolakopoulos S, Dalekos GN.

Antivir Ther. 2018;23(8):711. doi: 10.3851/IMP3261. No abstract available.

PMID:
30091421
6.

DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B.

Papatheodoridis GV, Rigopoulou EI, Papatheodoridi M, Zachou K, Xourafas V, Gatselis N, Hadziyannis E, Vlachogiannakos J, Manolakopoulos S, Dalekos GN.

Antivir Ther. 2018;23(8):677-685. doi: 10.3851/IMP3256. Erratum in: Antivir Ther. 2018;23(8):711.

PMID:
30044765
7.

Increased Frequency of Peripheral B and T Cells Expressing Granulocyte Monocyte Colony-Stimulating Factor in Rheumatoid Arthritis Patients.

Makris A, Adamidi S, Koutsianas C, Tsalapaki C, Hadziyannis E, Vassilopoulos D.

Front Immunol. 2018 Jan 10;8:1967. doi: 10.3389/fimmu.2017.01967. eCollection 2017.

8.

Response to Lipopolysaccharide binding protein predicts decompensated cirrhosis mortality? It is too early.

Agiasotelli D, Alexopoulou A, Vasilieva L, Hadziyannis E, Goukos D, Daikos GL, Dourakis SP.

Liver Int. 2017 Jul;37(7):1085-1086. doi: 10.1111/liv.13313. No abstract available.

PMID:
28635167
9.

Hepatitis B s antigen kinetics during treatment with nucleos(t)ides analogues in patients with hepatitis B e antigen-negative chronic hepatitis B.

Striki A, Manolakopoulos S, Deutsch M, Kourikou A, Kontos G, Kranidioti H, Hadziyannis E, Papatheodoridis G.

Liver Int. 2017 Nov;37(11):1642-1650. doi: 10.1111/liv.13432. Epub 2017 Apr 26.

PMID:
28345181
10.

Serum levels of vascular endothelial growth factor in non-alcoholic fatty liver disease.

Papageorgiou MV, Hadziyannis E, Tiniakos D, Georgiou A, Margariti A, Kostas A, Papatheodoridis GV.

Ann Gastroenterol. 2017;30(2):209-216. doi: 10.20524/aog.2016.0107. Epub 2016 Dec 1.

11.

High serum lipopolysaccharide binding protein is associated with increased mortality in patients with decompensated cirrhosis.

Agiasotelli D, Alexopoulou A, Vasilieva L, Hadziyannis E, Goukos D, Daikos GL, Dourakis SP.

Liver Int. 2017 Apr;37(4):576-582. doi: 10.1111/liv.13264. Epub 2016 Oct 31.

PMID:
27712029
12.

Changes in serum transforming growth factor-β1 levels in chronic hepatitis C patients under antiviral therapy.

Kotsiri I, Hadziyannis E, Georgiou A, Papageorgiou MV, Vlachogiannakos I, Papatheodoridis G.

Ann Gastroenterol. 2016 Jan-Mar;29(1):79-84.

13.

Serum HBsAg kinetics and usefulness of interferon-inducible protein 10 serum in HBeAg-negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate.

Papatheodoridis G, Triantos C, Hadziyannis E, Zisimopoulos K, Georgiou A, Voulgaris T, Vlachogiannakos I, Nikolopoulou V, Manolakopoulos S.

J Viral Hepat. 2015 Dec;22(12):1079-87. doi: 10.1111/jvh.12434. Epub 2015 Jul 6.

PMID:
26146764
14.

Cryoglobulinemic purpura in visceral leishmaniasis.

Petraki A, Kittou N, Hadziyannis E, Dourakis SP.

J Infect. 2015 Aug;71(2):271-3. doi: 10.1016/j.jinf.2015.03.002. Epub 2015 Mar 12. No abstract available.

PMID:
25773730
15.
16.

Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases.

Hatzara C, Hadziyannis E, Kandili A, Koutsianas C, Makris A, Georgiopoulos G, Vassilopoulos D.

Ann Rheum Dis. 2015 Oct;74(10):1848-53. doi: 10.1136/annrheumdis-2014-205376. Epub 2014 May 22.

PMID:
24854354
17.

Letter: do interferon lambda 3 polymorphisms predict the outcome of interferon therapy in hepatitis B infection?

Hadziyannis SJ, Laras A, Hadziyannis E.

Aliment Pharmacol Ther. 2014 May;39(10):1250-1. doi: 10.1111/apt.12719. No abstract available.

18.

Significance of the 13C-caffeine breath test for patients with cirrhosis.

Konstantinou D, Margariti E, Hadziyannis E, Pectasides D, Papatheodoridis GV.

Ann Gastroenterol. 2014;27(1):53-59.

19.

Interleukin-8 as a predictor of acute idiopathic pericarditis recurrences. A pilot study.

Vasileiou P, Tsioufis C, Lazaros G, Hadziyannis E, Kasiakogias A, Stefanadis C, Kallikazaros I, Vassilopoulos D.

Int J Cardiol. 2014 Apr 1;172(3):e463-4. doi: 10.1016/j.ijcard.2014.01.029. Epub 2014 Jan 22. No abstract available.

PMID:
24485643
20.

Hepatitis B surface antigen quantification in chronic hepatitis B and its clinical utility.

Hadziyannis E, Hadziyannis SJ.

Expert Rev Gastroenterol Hepatol. 2014 Feb;8(2):185-95. doi: 10.1586/17474124.2014.876362. Review.

PMID:
24417264
21.

The natural course of chronic hepatitis B virus infection and its management.

Hadziyannis SJ, Vassilopoulos D, Hadziyannis E.

Adv Pharmacol. 2013;67:247-91. doi: 10.1016/B978-0-12-405880-4.00007-X. Review.

PMID:
23886003
22.

Clinical characteristics, spontaneous clearance and treatment outcome of acute hepatitis C: a single tertiary center experience.

Deutsch M, Papadopoulos N, Hadziyannis ES, Koskinas J.

Saudi J Gastroenterol. 2013 Mar-Apr;19(2):81-5. doi: 10.4103/1319-3767.108479.

23.

Hepatitis C virus (HCV)-related cryoglobulinemia: cryoglobulin type and anti-HCV profile.

Minopetrou M, Hadziyannis E, Deutsch M, Tampaki M, Georgiadou A, Dimopoulou E, Vassilopoulos D, Koskinas J.

Clin Vaccine Immunol. 2013 May;20(5):698-703. doi: 10.1128/CVI.00720-12. Epub 2013 Mar 6.

24.

Is HCV core antigen a reliable marker of viral load? An evaluation of HCV core antigen automated immunoassay.

Hadziyannis E, Minopetrou M, Georgiou A, Spanou F, Koskinas J.

Ann Gastroenterol. 2013;26(2):146-149.

25.

Analysis of serum α-fetoprotein-L3% and des-γ carboxyprothrombin markers in cases with misleading hepatocellular carcinoma total α-fetoprotein levels.

Hadziyannis E, Sialevris K, Georgiou A, Koskinas J.

Oncol Rep. 2013 Feb;29(2):835-9. doi: 10.3892/or.2012.2147. Epub 2012 Nov 20.

PMID:
23174906
26.

Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.

Mitroulis I, Hatzara C, Kandili A, Hadziyannis E, Vassilopoulos D.

Ann Rheum Dis. 2013 Feb;72(2):308-10. doi: 10.1136/annrheumdis-2012-202088. Epub 2012 Aug 28. No abstract available.

PMID:
22930597
27.

Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir.

Hadziyannis SJ, Sevastianos V, Rapti I, Vassilopoulos D, Hadziyannis E.

Gastroenterology. 2012 Sep;143(3):629-636.e1. doi: 10.1053/j.gastro.2012.05.039. Epub 2012 May 31.

PMID:
22659218
28.

Comparison of two gamma interferon release assays and tuberculin skin testing for tuberculosis screening in a cohort of patients with rheumatic diseases starting anti-tumor necrosis factor therapy.

Vassilopoulos D, Tsikrika S, Hatzara C, Podia V, Kandili A, Stamoulis N, Hadziyannis E.

Clin Vaccine Immunol. 2011 Dec;18(12):2102-8. doi: 10.1128/CVI.05299-11. Epub 2011 Oct 12.

29.

Changes of serum levels of keratin-18 fragments in hepatitis B e antigen-negative chronic hepatitis B patients under oral antiviral therapy.

Giannousis IP, Manolakopoulos SG, Hadziyannis E, Georgiou A, Papatheodoridis GV.

Antivir Ther. 2011;16(4):505-14. doi: 10.3851/IMP1775.

PMID:
21685538
30.

Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B.

Manesis EK, Papatheodoridis GV, Tiniakos DG, Hadziyannis ES, Agelopoulou OP, Syminelaki T, Papaioannou C, Nastos T, Karayiannis P.

J Hepatol. 2011 Jul;55(1):61-8. doi: 10.1016/j.jhep.2010.10.027. Epub 2010 Dec 5.

PMID:
21145875
31.

Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.

Vassilopoulos D, Apostolopoulou A, Hadziyannis E, Papatheodoridis GV, Manolakopoulos S, Koskinas J, Manesis EK, Archimandritis AI.

Ann Rheum Dis. 2010 Jul;69(7):1352-5. doi: 10.1136/ard.2009.127233. Epub 2010 May 14.

PMID:
20472596
32.

Serum hepcidin levels are related to the severity of liver histological lesions in chronic hepatitis C.

Tsochatzis E, Papatheodoridis GV, Koliaraki V, Hadziyannis E, Kafiri G, Manesis EK, Mamalaki A, Archimandritis AJ.

J Viral Hepat. 2010 Nov;17(11):800-6. doi: 10.1111/j.1365-2893.2009.01244.x.

PMID:
20002304
33.

Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic Fatty liver disease.

Papatheodoridis GV, Hadziyannis E, Tsochatzis E, Georgiou A, Kafiri G, Tiniakos DG, Margariti K, Manolakopoulos S, Manesis EK, Archimandritis AJ.

J Clin Gastroenterol. 2010 Apr;44(4):e87-95. doi: 10.1097/MCG.0b013e3181c0945a.

PMID:
19881359
34.

Circulating and liver tissue levels of retinol-binding protein-4 in non-alcoholic fatty liver disease.

Schina M, Koskinas J, Tiniakos D, Hadziyannis E, Savvas S, Karamanos B, Manesis E, Archimandritis A.

Hepatol Res. 2009 Oct;39(10):972-8. doi: 10.1111/j.1872-034X.2009.00534.x. Epub 2009 Jul 13.

PMID:
19624771
35.

Serum HCV RNA levels and HCV genotype do not affect insulin resistance in nondiabetic patients with chronic hepatitis C: a multicentre study.

Tsochatzis E, Manolakopoulos S, Papatheodoridis GV, Hadziyannis E, Triantos C, Zisimopoulos K, Goulis I, Tzourmakliotis D, Akriviadis E, Manesis EK, Archimandritis AJ.

Aliment Pharmacol Ther. 2009 Nov 1;30(9):947-54. doi: 10.1111/j.1365-2036.2009.04094.x. Epub 2009 Jul 9.

36.
37.

Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity.

Tsochatzis E, Papatheodoridis GV, Hadziyannis E, Georgiou A, Kafiri G, Tiniakos DG, Manesis EK, Archimandritis AJ.

Scand J Gastroenterol. 2008;43(9):1128-36. doi: 10.1080/00365520802085387.

PMID:
18609175
38.

Cellular immune responses in hepatitis B virus e antigen negative chronic hepatitis B.

Vassilopoulos D, Rapti I, Nikolaou M, Hadziyannis E, Hadziyannis SJ.

J Viral Hepat. 2008 Nov;15(11):817-26. doi: 10.1111/j.1365-2893.2008.00996.x. Epub 2008 Jun 11.

PMID:
18554242
39.
40.

Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection.

Papatheodoridis GV, Chrysanthos N, Hadziyannis E, Cholongitas E, Manesis EK.

J Viral Hepat. 2008 Jun;15(6):434-41. doi: 10.1111/j.1365-2893.2007.00957.x. Epub 2008 Jan 9.

PMID:
18194171
41.
42.

Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection.

Papatheodoridis GV, Hadziyannis E, Tsochatzis E, Chrysanthos N, Georgiou A, Kafiri G, Manolakopoulos S, Tiniakos DG, Giannousis I, Manesis EK, Archimandritis AJ.

Gut. 2008 Apr;57(4):500-6. Epub 2007 Nov 19.

PMID:
18025069
43.

Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring.

Manesis EK, Schina M, Le Gal F, Agelopoulou O, Papaioannou C, Kalligeros C, Arseniou V, Manolakopoulos S, Hadziyannis ES, Gault E, Koskinas J, Papatheodoridis G, Archimandritis AJ.

Antivir Ther. 2007;12(3):381-8.

PMID:
17591028
44.

First appearance of Crohn's disease following infliximab treatment for spondylarthropathy.

Tsochatzis E, Vassilopoulos D, Manesis EK, Papatheodoridis G, Bousiotou A, Hadziyannis E, Archimandritis AJ.

Scand J Gastroenterol. 2007 Jun;42(6):784-5. No abstract available.

PMID:
17506005
45.

Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels.

Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ.

Antivir Ther. 2007;12(1):73-82.

PMID:
17503750
46.

Severe hepatitis C virus-related cryoglobulinaemic sensory-motor polyneuropathy treated with pegylated interferon-a2b and ribavirin: clinical, laboratory and neurophysiological study.

Koskinas J, Kilidireas C, Karandreas N, Kountouras D, Savvas S, Hadziyannis E, Archimandritis AJ.

Liver Int. 2007 Apr;27(3):414-20.

PMID:
17355465
47.

Thrombotic thrombocytopenic purpura with fatal outcome in a patient with chronic hepatitis C treated with pegylated interferon-a/2b.

Deutsch M, Manesis EK, Hadziyannis E, Vassilopoulos D, Archimandritis AJ.

Scand J Gastroenterol. 2007 Mar;42(3):408-9. No abstract available.

PMID:
17354123
48.

Hepatic steatosis in genotype 4 chronic hepatitis C is mainly because of metabolic factors.

Tsochatzis E, Papatheodoridis GV, Manesis EK, Chrysanthos N, Kafiri G, Petraki K, Hadziyannis E, Pandelidaki H, Zafiropoulou R, Savvas S, Koskinas J, Archimandritis AJ.

Am J Gastroenterol. 2007 Mar;102(3):634-41.

PMID:
17222326
49.

Study of host and virological factors of patients with chronic HCV infection and associated laboratory or clinical autoimmune manifestations.

Vassilopoulos D, Younossi ZM, Hadziyannis E, Boparai N, Yen-Lieberman B, Hsi E, Villa-Forte A, Ball E, Kimberly RP, Calabrese LH.

Clin Exp Rheumatol. 2003 Nov-Dec;21(6 Suppl 32):S101-11.

PMID:
14740435
50.

Cross-class resistance to non-beta-lactam antimicrobials in extended-spectrum beta-lactamase-producing Klebsiella pneumoniae.

Procop GW, Tuohy MJ, Wilson DA, Williams D, Hadziyannis E, Hall GS.

Am J Clin Pathol. 2003 Aug;120(2):265-7.

PMID:
12931557

Supplemental Content

Loading ...
Support Center